Treatment options for breast cancer and bone metastases.
The most common destination for breast cancer metastases is bone. If bone metastases are detected, treatment algorithms should include the continuation of cytoreductive therapy with the addition of treatment to counter skeletal-related events, including bone pain. The range of current treatment options includes bisphosphonates, surgical intervention to improve structural integrity and palliative focal radiotherapy. This article focuses on the role of bisphosphonate therapy in metastatic breast cancer. Bisphosphonate therapy significantly reduces the impact of skeletal-related events, reduces bone pain and increases patient quality of life. Our current understanding is that bisphosphonates may also disrupt the metastatic process and reduce the development of bone lesions. Ultimately, this may lead to further expansion of bisphosphonate-based therapy in the future.
Pecherstorfer
Martin
M
Hematologic-Oncologic Service, Landesklinikum Krems, Krems, Austria. martin.pecherstorfer@krems.lknoe.at
D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000175:diagnosis / Q000556:secondary* / Q000628:therapy*; D001862:Bone Resorption / Q000517:prevention & control; D001943:Breast Neoplasms / Q000473:pathology / Q000628:therapy*; D017024:Chemotherapy, Adjuvant; D004164:Diphosphonates / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D011788:Quality of Life; D018714:Radiotherapy, Adjuvant; D016032:Randomized Controlled Trials as Topic
D050071:Bone Density Conservation Agents; D004164:Diphosphonates